Business Context and Reporting Period
This Form 8-K Current Report was filed by SeaStar Medical Holding Corporation on November 12, 2025. The report discloses a material corporate governance event: the appointment of a new Chief Financial Officer.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes
- Executive Appointment: The Board of Directors appointed Michael Messinger as Chief Financial Officer, effective November 14, 2025.
- Compensation Structure: Under a Consulting Agreement dated October 31, 2025, Mr. Messinger will receive a monthly fee of $15,000.
- Termination Terms: The Company may terminate the Consulting Agreement at any time with 30 days' notice.
Management Commentary and Background
Mr. Messinger brings over two decades of experience in financing and accounting for drug discovery and development organizations. His recent background includes:
- Chief Financial Officer of ContraFect Corporation (October 2018 – November 2023), where he led financing rounds involving Pfizer Inc. and secured a contract with BARDA.
- Board member of Filament Health Corp. (since March 2024).
- Strategic consultant to various biotechnology companies (since January 2024).
- Previous senior financial roles at Lexicon Pharmaceuticals, Inc. and Coelacanth Corporation.
- Education: B.B.A. in accounting from the University of Michigan.
Investor Verification Checklist
- Verify the effective start date of the CFO role (November 14, 2025) against internal transition plans.
- Review the full text of the Consulting Agreement (Exhibit 10.1) for any additional compensation terms, equity grants, or non-compete clauses not summarized in the 8-K.
- Confirm the press release (Exhibit 99.1) for any strategic messaging regarding the company's financial direction under new leadership.
- Note that the filing does not provide updated financial statements; investors should refer to the most recent 10-Q or 10-K for current financial health.